Exosomes play a key role in facilitating cellto-cell communication in the cancer prognosis. Exosomes suppresses the immune function by inducing apoptosis of activated cytotoxic T cells, which enable tumor progression in the human body.
The key players of the world Exosome Diagnostic and Therapeutic Market are employing novel concepts and ideas to improve exosome isolation techniques and the current set of products, and also enhance their profitability so as to gain a competitive edge over the other market players.
The global market is expected to garner $367 million by 2022, registering a CAGR of 37.8% during the period 2016-2022. Diagnostic application segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America accounted for more than half of the world exosome diagnostic and therapeutic market share in 2015.
This report covers information on various types of exosome products such as instruments, reagents, and software that are manufactured for medical and research purposes in compliance with the European Medical Association (EMA), the U.S. Food and Drugs Administration (FDA), Conformit Europene (CE) and other regulatory authorities. Moreover, this study on the global exosome diagnostic and therapeutic market also focuses on the application and end users of the market. By application, the market is segmented into diagnostic and therapeutic applications. Based on end user, the market is categorized into cancer institute, hospital, diagnostic centers, and others.
North America and Europe together accounted for more than three-fourths share of overall market in 2015, and is expected to maintain this lead throughout the forecast period. The growth in the exosome diagnostic and therapeutic market in these regions attributes to the technological advancement in the isolation of exosomes, innovative and advanced applications of exosome-based products, and geriatric population coupled with increase in incidence of diseases such as cancer and cardiovascular diseases. However, Asia-Pacific is projected to be the fastest-growing region, registering a CAGR of 38.8% during the analysis period. This is mainly due to the increase in awareness of innovative and advanced applications of exosome-based diagnostic and therapeutic products. In addition, increase in research outsourcing from emerging markets, improvement of healthcare infrastructures, and increase in expenditures in the emerging markets (such as India and China) have boosted the market growth.
Get the PDF brochure of this market insight@ https://www.alliedmarketresearch.com/request-sample/1723
Key findings of Exosome Diagnostic and Therapeutic Market:
- In 2015, diagnostic application was the leading segment of overall exosome diagnostic and therapeutic market revenue, and is projected to grow at a CAGR of 41.5% during the forecast period.
- Software segment is expected to grow at a remarkable CAGR of 38.3%, owing to increased demand in the life science research studies.
- North America accounted for over half of the world exosome diagnostic and therapeutic market in 2015.
- The cancer institute segment is projected to be the largest revenue-generating end user segment in the world exosome diagnostic and therapeutic market during the forecast period.
- Japan alone is the major shareholder in the Asia-Pacific region accounting for about two-fifth share of the Asia-Pacific exosome diagnostic and therapeutic market.
Exosomes suppresses the immune function by inducing apoptosis of activated cytotoxic T cells, which enable tumor progression in the human body. In addition, exosomes also stimulate the angiogenesis and migration leading to metastasis. Moreover, exosomes trigger apoptosis in anti-tumor immune cells through tumor necrosis factor pathways. Furthermore, healthcare professionals use exosomes to diagnose cancer, which helps in profiling genetic changes in tumors and also prevent the spread of the disease.